Theresa Zhang
Overview
Explore the profile of Theresa Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anagnostou V, Smith K, Forde P, Niknafs N, Bhattacharya R, White J, et al.
Cancer Discov
. 2016 Dec;
7(3):264-276.
PMID: 28031159
Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance...
2.
Guertin A, ONeil J, Stoeck A, Reddy J, Cristescu R, Haines B, et al.
Mol Cancer Ther
. 2016 Jun;
15(8):1998-2008.
PMID: 27256377
Targeting surface receptors overexpressed on cancer cells is one way to specifically treat cancer versus normal cells. Vintafolide (EC145), which consists of folate linked to a cytotoxic small molecule, desacetylvinblastine...
3.
ONeil J, Benita Y, Feldman I, Chenard M, Roberts B, Liu Y, et al.
Mol Cancer Ther
. 2016 Mar;
15(6):1155-62.
PMID: 26983881
Combination drug therapy is a widely used paradigm for managing numerous human malignancies. In cancer treatment, additive and/or synergistic drug combinations can convert weakly efficacious monotherapies into regimens that produce...
4.
Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley D, et al.
Sci Transl Med
. 2015 Apr;
7(283):283ra53.
PMID: 25877891
Massively parallel sequencing approaches are beginning to be used clinically to characterize individual patient tumors and to select therapies based on the identified mutations. A major question in these analyses...
5.
Di Cosimo S, Sathyanarayanan S, Bendell J, Cervantes A, Stein M, Brana I, et al.
Clin Cancer Res
. 2014 Oct;
21(1):49-59.
PMID: 25320355
Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin-like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro...
6.
Booher R, Hatch H, Dolinski B, Nguyen T, Harmonay L, Al-Assaad A, et al.
PLoS One
. 2014 Oct;
9(10):e108371.
PMID: 25289887
Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer. Additional understanding of antitumor mechanisms and identification of predictive biomarkers are important for...
7.
Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, et al.
Cancer Discov
. 2014 Aug;
4(10):1154-67.
PMID: 25104330
Unlabelled: Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative...
8.
Zhang W, Haines B, Efferson C, Zhu J, Ware C, Kunii K, et al.
Transl Oncol
. 2013 Jan;
5(6):422-9.
PMID: 23323157
Activation of the phosphoinositide 3-kinase pathway is commonly observed in human prostate cancer. Loss of function of phosphatase and tensin homolog (PTEN) is associated with the activation of AKT and...
9.
Andersen J, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen A, et al.
Sci Transl Med
. 2010 Aug;
2(43):43ra55.
PMID: 20686178
Although we have made great progress in understanding the complex genetic alterations that underlie human cancer, it has proven difficult to identify which molecularly targeted therapeutics will benefit which patients....
10.
Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, et al.
BMC Med Genomics
. 2010 Jul;
3:26.
PMID: 20591134
Background: Hyperactivation of the Ras signaling pathway is a driver of many cancers, and RAS pathway activation can predict response to targeted therapies. Therefore, optimal methods for measuring Ras pathway...